Argentina Pulmonary Arterial Hypertension Market Size & Outlook
Argentina pulmonary arterial hypertension market, 2018-2030 (US$M)
Related Markets
Argentina pulmonary arterial hypertension market highlights
- The Argentina pulmonary arterial hypertension market generated a revenue of USD 149.3 million in 2023 and is expected to reach USD 222.2 million by 2030.
- The Argentina market is expected to grow at a CAGR of 5.8% from 2024 to 2030.
- In terms of segment, prostacyclin and prostacyclin analogs was the largest revenue generating drug class in 2023.
- PDE-5 Inhibitors is the most lucrative drug class segment registering the fastest growth during the forecast period.
Pulmonary arterial hypertension market data book summary
| Market revenue in 2023 | USD 149.3 million |
| Market revenue in 2030 | USD 222.2 million |
| Growth rate | 5.8% (CAGR from 2023 to 2030) |
| Largest segment | Prostacyclin and prostacyclin analogs |
| Fastest growing segment | PDE-5 Inhibitors |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators |
| Key market players worldwide | United Therapeutics Corp, Bayer AG, Gilead Sciences Inc, Johnson & Johnson, Viatris Inc, GlaxoSmithKline, Sandoz Group AG ADR, Lupin, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd |
Other key industry trends
- In terms of revenue, Argentina accounted for 2.0% of the global pulmonary arterial hypertension market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Latin America, Brazil pulmonary arterial hypertension market is projected to lead the regional market in terms of revenue in 2030.
- Mexico is the fastest growing regional market in Latin America and is projected to reach USD 263.8 million by 2030.
Prostacyclin and prostacyclin analogs was the largest segment with a revenue share of 47.49% in 2023. Horizon Databook has segmented the Argentina pulmonary arterial hypertension market based on endothelin receptor antagonists (eras), pde-5 inhibitors, prostacyclin and prostacyclin analogs, sgc stimulators covering the revenue growth of each sub-segment from 2018 to 2030.
Argentina is expected to exhibit lucrative CAGR during the forecast period. These are expected to promote higher penetration of international players within the region. Increasing per capita income of consumers and rising respiratory disease in this region is thereby driving the growth of the pulmonary arterial hypertension market.
According to WHO, in 2016, 10.2% of people were diabetic while 62.2% were overweight. Such a high prevalence of diabetes and its associated factors may propel the country’s market.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pulmonary Arterial Hypertension Market Scope
Pulmonary Arterial Hypertension Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Argentina pulmonary arterial hypertension market size, by drug class, 2018-2030 (US$M)
Argentina Pulmonary Arterial Hypertension Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
